Failed Drug Data Are Important For “Critical Path” Improvements – Report
Executive Summary
Lessons gleaned from FDA and industry data on late-stage product failures could be used to improve the drug development process, participants at a conference on FDA's "Critical Path" initiative suggested
You may also be interested in...
Increasing Clinical Trial Failures Highlighted In GAO Report On Drug R&D
A "systematic analysis" of why drugs fail during clinical testing could help curb the rising number of trial failures and prevent companies from repeating others' trial mistakes, the Government Accountability Office suggests in a recent report
Increasing Clinical Trial Failures Highlighted In GAO Report On Drug R&D
A "systematic analysis" of why drugs fail during clinical testing could help curb the rising number of trial failures and prevent companies from repeating others' trial mistakes, the Government Accountability Office suggests in a recent report
FDA Seeks Advisory Role In Facilitating Critical Path Research
FDA expects to play the role of a "neutral referee" to facilitate external research conducted under the agency's Critical Path initiative